BMS withdraws Ixempra in Europe
Executive Summary
Bristol-Myers Squibb has withdrawn its application to market Ixempra (ixabepilone) in Europe, the European Medicines Agency announced March 19. The metastatic breast cancer drug gained U.S. approval for a fourth-line indication as monotherapy in a salvage setting, and as third-line combination therapy based on progression-free survival - an endpoint that FDA was concerned would not translate to overall survival benefit, according to agency review documents (1Pharmaceutical Approvals Monthly, June 1, 2008, p. 36). In Europe, Ixempra was proposed for in combination with capecitabine to treat locally advanced or metastatic breast cancer after failure of previous cytotoxic chemotherapy treatments. It had received a negative opinion from CHMP
You may also be interested in...
FDA Cleared Ixempra Despite Doubts Over Chance Of Showing Survival Benefit
Doubts about the likelihood that the improvement in progression-free survival seen in a pivotal trial of Bristol-Myers Squibb's Ixempra (ixabepilone) will translate to an overall survival advantage could add to the controversy over the appropriateness of PFS as a surrogate for survival in metastatic breast cancer.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.